The Increasing Cases of Cancerous Tumours Are Encouraging Pituitary Cancer Market Growth

Pune, India, January, 2018/MRFR Press Release/- Market Research Future published a Half – Cooked research report on “Global Pituitary cancer Market Research Report - Forecast to 2022” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022.

Trinity Biotech (Ireland), Bupa International, Salzman International (US), Genentech, Inc., Sigma-Aldrich Co. LLC, Validus Pharmaceuticals, Inc., Alembic Limited, Pfizer Inc. and others are some of the prominent players at the forefront of competition in the global pituitary cancer market and are profiled in MRFR Analysis. 

Global Pituitary Cancer Market   - Overview

The Pituitary Cancer market is projected to reach USD 736.4 Million by 2030 at 7.8% CAGR during the forecast period 2022-2030

Pituitary gland is a very small gland responsible for producing hormones which regulates critical body organs and glands. It is located behind the eyes and below the front side of the brain. It is a very rare type of cancer. Only a few hundred pituitary cancers have ever been recorded till the date. Most of those were diagnosed in older people. Most pituitary tumours are noncancerous (benign) in nature. According to the American Cancer Society, few of the 10,000 tumors projected to be diagnosed in 2016 will turn out to be cancerous.

The pituitary gland is connected directly to part of the brain called the hypothalamus. This provides a key link between the brain and the endocrine system, a collection of glands in the body that make hormones. The hypothalamus releases hormones into tiny blood vessels connected to the pituitary gland. These then cause the pituitary gland to make its own hormones. The pituitary is considered the “master control gland” because it makes the hormones that control the levels of hormones made by most of the other endocrine glands in the body.

Benign tumors account for about 30 to 40 percent of all pituitary tumors, according to the American Brain Tumor Association. They are most common in young, reproductive-age women and men in their 40s and 50s. One in 4 people may have a benign pituitary tumor (adenoma) and not even know it because the tumor is noncancerous and doesn’t cause any symptoms. Pituitary tumors are often considered brain tumors, and they make up 12 to 19 percent of all primary brain tumors. But most pituitary tumors are benign and most of them are treatable.

Many different kinds of drugs can be used to treat pituitary cancer such as Pasireotide (Signifor) is a somatostatin analogs, Cabergoline (Dostinex) and bromocriptine (Parlodel) are most commonly used as dopamine agonists. Pegvisomant (Somavert) is the novel drug under the class of growth hormone antagonists. The corticotropin (ACTH)-secreting tumors drugs such as Cyproheptadine (Periactin) is an antihistamine drug that can suppress ACTH production in some of these tumors. Mifepristone (Korlym) is a type of drug called a cortisol receptor blocker. It limits the effects of cortisol on other tissues in the body.

The global pituitary cancer market is growing exponentially owing to the increasing prevalence of cancerous tumors and hormonal imbalances these factor are contributing to the growth of the market. 

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Pituitary Cancer Market Research Report

Global Pituitary Cancer Market -

Regional Analysis

Global pituitary cancer market, on the basis of regions is divided into North America, Europe, Asia Pacific and Middle East and Africa.

On regional, North America has the largest market for the pituitary cancer. The major factor for the growth of this market in North America is robust research & development practices and growing advancements in the field of neurology. Increasing cases of cancer is the major factor for providing a good platform for the growth of the market. US is the highest contributor for the market of pituitary cancer which is followed by Canada.  Pituitary cancer (pituitary carcinoma) is rare. Only a few hundred cases of pituitary cancers have ever been recorded in the United States. Most were diagnosed in older people and about 75 percent of cases were diagnosed after death.

Europe has a runner-up market for pituitary cancer. Adoption of sedentary lifestyle and increase in workload is the major factor for the causing pituitary cancer to the patient in Europe. UK and Germany are the major contributor for the market. Due to presence of many of the major companies in this region has developed pituitary cancer market in this region.

Asia Pacific is the fastest growing market and is expecting to take Europe position for pituitary cancer market. Increasing work load and a huge development in healthcare sector has boosted this market in Asia Pacific region. Middle East and Africa contribute the least market in pituitary cancer. Due to less infrastructure development and limited growth in healthcare sector is the factor for less market in Africa.